Terns Pharmaceuticals, Inc.

NASDAQ•TERN

執行長: Ms. Amy L. Burroughs M.B.A.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-02-05

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

聯絡資訊

1065 East Hillsdale Boulevard, Suite 100, Foster City, CA, 94404, United States

650-525-5535

www.ternspharma.com

市值

$3.83B

本益比 (TTM)

-41.3

19.7

股息率

52周最高

$48.26

52周最低

$1.87

52周範圍

88%

排名50Top 68.9%

3.1

F-Score

改良版 Piotroski 分析

基於 7 年期基本面

疲弱 • 3.1 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2019-2025

財務儀表板

Q3 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.27-3.57%

近4季度走勢

自由現金流

-$19.77M+20.16%

近4季度走勢

2025 Q3 財報亮點

核心亮點

TERN-701 Clinical Data Update Nine-month data shows 75% cumulative MMR rate by 24 weeks in CARDINAL trial efficacy-evaluable patients.

Cash Runway Secured Cash reserves of $150.7M are sufficient to fund planned operating expenses and capital requirements into 2028.

R&D Investment Rises Nine-month R&D expenses increased $6.9M to $59.0M, driven by clinical and preclinical program advancement.

Stock-Based Costs Decline Total stock-based compensation expense was $10.0M for nine months, decreasing from $12.6M prior period.

關注風險

Regulatory Agency Disruption FDA funding cuts and potential government shutdowns could hinder timely guidance and product approval timelines.

Metabolic Asset Pivot Company decided not to advance TERN-601 or invest further in TERN-501 or the TERN-800 series assets.

Substantial Future Funding Expect continued net operating losses requiring substantial additional funding to support ongoing research and development activities.

Trade Policy Uncertainty Evolving global trade policies and tariffs, especially concerning China operations, pose risks to supply chain costs.

未來展望

Focus on TERN-701 Advancement Strategy reiterates rapid advancement of TERN-701 program across all Chronic Myeloid Leukemia treatment lines.

Seeking TERN-501 Partner Actively seeking strategic partner to advance TERN-501 program for obesity and other metabolic disorders.

Increased Operating Expenses Expect expenses to increase as development continues for ongoing clinical trials and future regulatory submissions.

同行對比

營業收入 (TTM)

ARVN

$262.60M

-0.3%

SNDX

$172.35M

+627.8%

DAWN

$158.18M

+20.6%

毛利率 (最新季度)

SNDX

102.3%

-13.9pp

IMTX

100.0%

+0.0pp

NKTR

98.3%

+18.4pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
ERAS	$4.68B	-33.6	-33.1%	11.5%
TERN	$3.83B	-41.3	-30.0%	0.3%
OLMA	$1.91B	-13.9	-41.5%	1.3%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年3月19日

每股收益:-$0.30

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料